Nathan Jorgensen

Ph.D. 2007

Thesis Title:

Akt's role in SCA1 neurodegeneration

Current Position:

Chief Financial Officer, Voyager Therapeutics

Past Positions:

Chief Financial Officer, Vor Biopharma, Cambridge,  MA

Qatar Investment Authority

Postdoctoral Fellow, Columbia University

Undergraduate Institution and Major/Degree:

B.A. Saint Johns University Individualized Psychology

Major Advisor(s):

Harry T. Orr, Ph.D.

Research Description:

My current research involves the development of transgenic mice to cell-specifically regulate activity of protiens we believe will alter the pathogenesis of the cerebellar degenerative disease, Spinocerebellar Ataxia Type 1.

Lab Rotations:

  • Janet Dubinsky
  • Walter Low
  • Laura Ranum

Courses Taken Beyond the Core Courses:

  • Advanced Genetic
  • Advanced Human Genetics

Selected Publications:

  • Jorgensen ND, Peng Y, Ho CC, Rideout HJ, Petrey D, Liu P, Dauer WT. The WD40 domain is required for LRRK2 neurotoxicity. PLoS One. 2009;4(12):e8463.
  • Jorgensen ND, Andresen JM, Lagalwar S, Armstrong B, Stevens S, Byam CE, Duvick LA, Lai S, Jafar-Nejad P, Zoghbi HY, Clark HB, Orr HT. Phosphorylation of ATXN1 at Ser776 in the cerebellum. J Neurochem. 2009;110(2):675-686.
  • Jorgensen ND, Andresen JM, Pitt JE, Swenson MA, Zoghbi HY, Orr HT. Hsp70/Hsc70 regulates the effect phosphorylation has on stabilizing ataxin-1. J Neurochem. 2007;102(6):2040-2048.
  • Serra HG, Duvick L, Zu T, Carlson K, Stevens S, Jorgensen N , Lysholm A, Burright E, Zoghbi HY, Clark HB, Andresen JM, Orr HT. RORalpha-mediated Purkinje cell development determines disease severity in adult SCA1 mice. Cell. 2006;127(4):697-708.
Nathan Jorgensen